tacrolimus
Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
Cross Reference
Introduction
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with tacrolimus?
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (2)
- Am. J. Physiol. Renal Physiol. (1)
- Drug Metab. Dispos. (1)
- Others (1)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with tacrolimus
PubChem Associated disorders and diseases
What pathways are associated with tacrolimus
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with tacrolimus?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with tacrolimus?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with tacrolimus?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with tacrolimus?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with tacrolimus?
There are no associated biomedical information in the current reference collection.
NCBI Entrez Crosslinks
All references with tacrolimus
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Kim EJ et al. | Costimulation blockade alters germinal center responses and prevents antibody-mediated rejection. | 2014 | Am. J. Transplant. | pmid:24354871 |
| Frassetto LA et al. | Immunosuppressant pharmacokinetics and dosing modifications in HIV-1 infected liver and kidney transplant recipients. | 2007 | Am. J. Transplant. | pmid:17949460 |
| Dugast E et al. | Failure of Calcineurin Inhibitor (Tacrolimus) Weaning Randomized Trial in Long-Term Stable Kidney Transplant Recipients. | 2016 | Am. J. Transplant. | pmid:27367750 |
| de Fontbrune FS et al. | Veno-occlusive disease of the liver after lung transplantation. | 2007 | Am. J. Transplant. | pmid:17697264 |
| Krenzien F et al. | Age-Dependent Metabolic and Immunosuppressive Effects of Tacrolimus. | 2017 | Am. J. Transplant. | pmid:27754593 |
| Ekberg H et al. | Calcineurin inhibitor minimization in the Symphony study: observational results 3 years after transplantation. | 2009 | Am. J. Transplant. | pmid:19563339 |
| ter Meulen CG et al. | Steroid-withdrawal at 3 days after renal transplantation with anti-IL-2 receptor alpha therapy: a prospective, randomized, multicenter study. | 2004 | Am. J. Transplant. | pmid:15084178 |
| Mehra MR et al. | Immunosuppression in cardiac transplantation: science, common sense and the heart of the matter. | 2006 | Am. J. Transplant. | pmid:16686745 |
| Grimm M et al. | Superior prevention of acute rejection by tacrolimus vs. cyclosporine in heart transplant recipients--a large European trial. | 2006 | Am. J. Transplant. | pmid:16686762 |
| Hernández-Fisac I et al. | Tacrolimus-induced diabetes in rats courses with suppressed insulin gene expression in pancreatic islets. | 2007 | Am. J. Transplant. | pmid:17725683 |
| Hamdy AF et al. | Comparison of sirolimus with low-dose tacrolimus versus sirolimus-based calcineurin inhibitor-free regimen in live donor renal transplantation. | 2005 | Am. J. Transplant. | pmid:16162204 |
| Kaufman DB et al. | Alemtuzumab induction and prednisone-free maintenance immunotherapy in kidney transplantation: comparison with basiliximab induction--long-term results. | 2005 | Am. J. Transplant. | pmid:16162205 |
| Mujtaba MA et al. | Conversion from tacrolimus to belatacept to prevent the progression of chronic kidney disease in pancreas transplantation: case report of two patients. | 2014 | Am. J. Transplant. | pmid:25179306 |
| Schwarz A et al. | Polyoma virus nephropathy in native kidneys after lung transplantation. | 2005 | Am. J. Transplant. | pmid:16162212 |
| Böger CA et al. | Reverse diastolic intrarenal flow due to calcineurin inhibitor (CNI) toxicity. | 2006 | Am. J. Transplant. | pmid:16889550 |
| Tan HP et al. | Living donor renal transplantation using alemtuzumab induction and tacrolimus monotherapy. | 2006 | Am. J. Transplant. | pmid:16889606 |
| Lucey MR et al. | A comparison of tacrolimus and cyclosporine in liver transplantation: effects on renal function and cardiovascular risk status. | 2005 | Am. J. Transplant. | pmid:15816894 |
| Pillebout E et al. | Renal histopathological lesions after orthotopic liver transplantation (OLT). | 2005 | Am. J. Transplant. | pmid:15816895 |
| Chisholm-Burns MA et al. | Improving outcomes of renal transplant recipients with behavioral adherence contracts: a randomized controlled trial. | 2013 | Am. J. Transplant. | pmid:23819827 |
| Van Laecke S et al. | Posttransplantation hypomagnesemia and its relation with immunosuppression as predictors of new-onset diabetes after transplantation. | 2009 | Am. J. Transplant. | pmid:19624560 |
| Pescovitz MD et al. | A randomized, double-blind, pharmacokinetic study of oral maribavir with tacrolimus in stable renal transplant recipients. | 2009 | Am. J. Transplant. | pmid:19663892 |
| Mian AN et al. | Mycoplasma hominis septic arthritis in a pediatric renal transplant recipient: case report and review of the literature. | 2005 | Am. J. Transplant. | pmid:15636628 |
| Gregoor PS and Weimar W | Tacrolimus and pure red-cell aplasia. | 2005 | Am. J. Transplant. | pmid:15636632 |
| Gao R et al. | Effects of immunosuppressive drugs on in vitro neogenesis of human islets: mycophenolate mofetil inhibits the proliferation of ductal cells. | 2007 | Am. J. Transplant. | pmid:17391142 |
| Rodriguez-Rodriguez AE et al. | The higher diabetogenic risk of tacrolimus depends on pre-existing insulin resistance. A study in obese and lean Zucker rats. | 2013 | Am. J. Transplant. | pmid:23651473 |
| Tremblay S et al. | A Steady-State Head-to-Head Pharmacokinetic Comparison of All FK-506 (Tacrolimus) Formulations (ASTCOFF): An Open-Label, Prospective, Randomized, Two-Arm, Three-Period Crossover Study. | 2017 | Am. J. Transplant. | pmid:27340950 |
| Neuberger JM et al. | Delayed introduction of reduced-dose tacrolimus, and renal function in liver transplantation: the 'ReSpECT' study. | 2009 | Am. J. Transplant. | pmid:19120077 |
| Momper JD et al. | The impact of conversion from prograf to generic tacrolimus in liver and kidney transplant recipients with stable graft function. | 2011 | Am. J. Transplant. | pmid:21714845 |
| Lemahieu WP et al. | CYP3A4 and P-glycoprotein activity in healthy controls and transplant patients on cyclosporin vs. tacrolimus vs. sirolimus. | 2004 | Am. J. Transplant. | pmid:15307840 |
| Fan DM et al. | Successful ABO-incompatible living-related intestinal transplantation: a 2-year follow-up. | 2015 | Am. J. Transplant. | pmid:25808777 |
| Luan FL et al. | Comparative risk of impaired glucose metabolism associated with cyclosporine versus tacrolimus in the late posttransplant period. | 2008 | Am. J. Transplant. | pmid:18786231 |
| Woywodt A et al. | Different preparations of tacrolimus and medication errors. | 2008 | Am. J. Transplant. | pmid:18786238 |
| Levi Z et al. | Switching from tacrolimus to sirolimus halts the appearance of new sebaceous neoplasms in Muir-Torre syndrome. | 2007 | Am. J. Transplant. | pmid:17229076 |
| Mulay AV et al. | Impact of immunosuppressive medication on the risk of renal allograft failure due to recurrent glomerulonephritis. | 2009 | Am. J. Transplant. | pmid:19353768 |
| Ogawa T et al. | Rho-associated kinase inhibitor reduces tumor recurrence after liver transplantation in a rat hepatoma model. | 2007 | Am. J. Transplant. | pmid:17229077 |
| Miriuka SG et al. | mTOR inhibition induces endothelial progenitor cell death. | 2006 | Am. J. Transplant. | pmid:16796720 |
| Bourdeaux C et al. | Living-related versus deceased donor pediatric liver transplantation: a multivariate analysis of technical and immunological complications in 235 recipients. | 2007 | Am. J. Transplant. | pmid:17173657 |
| Mazariegos GV et al. | Dendritic cell subset ratio in tolerant, weaning and non-tolerant liver recipients is not affected by extent of immunosuppression. | 2005 | Am. J. Transplant. | pmid:15643991 |
| Bahra M et al. | MMF and calcineurin taper in recurrent hepatitis C after liver transplantation: impact on histological course. | 2005 | Am. J. Transplant. | pmid:15644002 |
| Rostaing L et al. | Alefacept combined with tacrolimus, mycophenolate mofetil and steroids in de novo kidney transplantation: a randomized controlled trial. | 2013 | Am. J. Transplant. | pmid:23730730 |
| Levy G et al. | REFINE: a randomized trial comparing cyclosporine A and tacrolimus on fibrosis after liver transplantation for hepatitis C. | 2014 | Am. J. Transplant. | pmid:24456049 |
| Triñanes J et al. | Deciphering Tacrolimus-Induced Toxicity in Pancreatic β Cells. | 2017 | Am. J. Transplant. | pmid:28432716 |
| Posselt AM et al. | Islet transplantation in type 1 diabetics using an immunosuppressive protocol based on the anti-LFA-1 antibody efalizumab. | 2010 | Am. J. Transplant. | pmid:20659093 |
| Ciancio G et al. | Advantage of rapamycin over mycophenolate mofetil when used with tacrolimus for simultaneous pancreas kidney transplants: randomized, single-center trial at 10 years. | 2012 | Am. J. Transplant. | pmid:22946986 |
| Jacobson PA et al. | Lower calcineurin inhibitor doses in older compared to younger kidney transplant recipients yield similar troughs. | 2012 | Am. J. Transplant. | pmid:22947444 |
| De Simone P et al. | Everolimus with reduced tacrolimus improves renal function in de novo liver transplant recipients: a randomized controlled trial. | 2012 | Am. J. Transplant. | pmid:22882750 |
| Echeverri GJ et al. | Endoscopic gastric submucosal transplantation of islets (ENDO-STI): technique and initial results in diabetic pigs. | 2009 | Am. J. Transplant. | pmid:19775318 |
| Gaston RS et al. | Fixed- or controlled-dose mycophenolate mofetil with standard- or reduced-dose calcineurin inhibitors: the Opticept trial. | 2009 | Am. J. Transplant. | pmid:19459794 |
| Gatault P et al. | Reduction of Extended-Release Tacrolimus Dose in Low-Immunological-Risk Kidney Transplant Recipients Increases Risk of Rejection and Appearance of Donor-Specific Antibodies: A Randomized Study. | 2017 | Am. J. Transplant. | pmid:27862923 |
| Brennan DC et al. | Incidence of BK with tacrolimus versus cyclosporine and impact of preemptive immunosuppression reduction. | 2005 | Am. J. Transplant. | pmid:15707414 |